Navigation Links
TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
Date:5/27/2008

SAN MARINO, Calif., May 27 /PRNewswire/ -- Epeius Biotechnologies (http://www.epeiusbiotech.com) announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery -- using Rexin-G followed by Reximmune-C -- for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles bearing a cytocidal cyclin G1 gene and a granulocyte-macrophage colony stimulating factor (GM-CSF) gene, respectively. When injected intravenously, these targeted vectors seek out and accumulate in cancerous lesions, thus increasing the effective local concentrations of the therapeutic nanoparticles within the tumors.

The working hypothesis behind this two-stage approach to cancer management predicts that strategic and individualized vaccination of a patient against his/her own cancer can be achieved by combining (1) the targeted vector bearing a potent cytocidal construct, Rexin-G, with (2) a targeted vector bearing an immune activating gene, Reximmune-C. Rexin-G is given first to kill the cancer cells and thus expose neoantigens within the tumors, followed by Reximmune-C to recruit the body's immune cells into the same tumor compartments, thereby prompting recognition of the tumor neoantigens in situ and inducing long-lasting anti-tumor immunity.

The purpose of the Phase I study was to evaluate the overall safety/toxicity and therapeutic potential of this sequential regimen, in an effort to achieve a personalized cancer vaccination in vivo. Seven patients with chemo-resistant cancer, including carcinoma of breast, colon and pancreas, non-small cell lung cancer and leiomyosarcoma, received Rexin-G i.v. at a dose of 4 x 10e10 cfu per day for 2 to 6 weeks (Cumulative Dose: 4.0 x 10e11 to 1.2 x 10e12 cfu) followed by Reximmune-C i.v. at 2.5 x 10e9 cfu for 5 days or 5
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
2. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
5. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
8. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
9. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... July 12, 2011 Particle Sciences ... Systems, a leading provider of pre-clinical pharmacokinetic services, ... together to provide their clients with enhanced drug ... the dosage form development scheme.   ...
... Helping Virologists Keep,Up- to- Date ... Elsevier ( http://www.elsevier.com ) has,announced the publication of the first ... in its prestigious Current Opinion,series, publishing six issues a year. ... filtered approach to the ever-expanding wealth of research,published on viruses and ...
Cached Medicine Technology:Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services 2Elsevier Launches Current Opinion in Virology 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... my mom’s stroke, she loss the use of her right side. ... his left side. Eating became a difficult task for them so ... enjoy eating again,” said an inventor, from Fayetteville, N.C. As a ... (P C H PLATE). , The PATRICIA CAROL HALL PLATE (P ... individuals who suffer from stroke, experience tremors or loss of movement. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... progression, mouse study suggests , , MONDAY, April 14 (HealthDay ... cholesterol and one is an anti-inflammatory -- may be ... presented at the American Association for Cancer Research annual ... and the statin Lipitor, when used together or alone, ...
... Kimmel Cancer Center at Thomas Jefferson University in ... blood pressure medications might help prevent the spread ... laboratory that one type of pressure-lowering drug called ... growth and causes cell death. , In earlier ...
... Real-Time In Vivo Data via Quantitative ... ... Inc., a leader,in fluorescence in vivo imaging, today announced the commercial ... is based on VisEn,s,proprietary Fluorescence Molecular Tomography (FMT(TM)) technology,platform, and combined ...
... 14 HealthFusion, a,national clearinghouse for ... center operation customer satisfaction excellence under ... Center Program(SM). This distinction,acknowledges a strong ... to provide "An Outstanding Customer Service ...
... As the first of the,nation,s 78 million baby boomers ... health care work force that is too small and ... new report from the Institute of,Medicine. The report calls ... providers -- not just specialists -- in the basics ...
... Denise Kehoe has joined,medication therapy management (MTM) company ... new role, she will manage and oversee the,expansion ... the country., Kehoe brings more than 15 ... PharmMD. She recently served as national strategic,executive of ...
Cached Medicine News:Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 2Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis 2Health News:PharmMD Announces Denise Kehoe as Vice President of Business Development 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
... bacterial growth system, combines orbital shaking, ... format for bacterial growth. It is ... HT-Prep™ Automatic DNA Extractor. The uniquely ... traditional floor shakers. Plate-holding cassettes allow ...
Medicine Products: